<DOC>
	<DOCNO>NCT03004638</DOCNO>
	<brief_summary>To evaluate safety pharmacokinetics , pharmacodynamics repeat weekly dosing MEDI6012 subject stable atherosclerosis .</brief_summary>
	<brief_title>Multiple Ascending Doses MEDI6012 Subjects With Stable Atherosclerotic Cardiovascular Disease</brief_title>
	<detailed_description>A Phase 2a Randomized , Blinded , Placebo-controlled Study Evaluate Safety , Pharmacokinetics Pharmacodynamics Multiple Ascending Doses MEDI6012 Subjects Stable Atherosclerotic Cardiovascular Disease</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Nonchildbearing potential Diagnosis stable atherosclerotic CVD Currently receive stable dose Statin Unstable cardiovascular condition within 3 month screen Elective arterial revascularization past month Any plan arterial revascularization Body mass index &lt; 18 &gt; 45 Clinically significant ECG may interfere interpretation serial ECG QT interval change screen Chronic kidney disease define estimate glomerular filtration rate le 30 mL/mim/1.73m2 Triglycerides great 500 mg/dL , LDLC great 160 mg/dL , HDLC great 60 male , 65 female Clinically significant vital sign abnormality Genetic disorder cholesterol metabolism History overt liver disease Poorly control endocrine disorder ( Diabetes Thyroid disorder ) Current recent use systemic corticosteroid Recent ongoing infection febrile illness History active malignancy within 5 year History alcohol recreational substance abuse past 6 month Concurrent enrollment another clinical study investigational drug therapy use biologicals within 6 month prior screen within 5 halflives investigational agent biologic , whichever longer .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>CAD</keyword>
	<keyword>Atherosclerotic Cardiovascular Disease</keyword>
</DOC>